Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
   
Ask the Experts About

Lipodystrophy and WastingLipodystrophy and Wasting
           
Rollover images to visit our other forums!
  
  • Email Email
  • Glossary Glossary


What percent get problems?
Oct 23, 2003

Hi Dr:

Have there been any studies indicating what percentage of persons with Hiv get lipo, both on and off meds?

What about persons on keletra. I started it one mont ago--treatment naive. Please help if you can.

Response from Dr. Moyle

Several studies have tried to address this. In a german study 30% of people on treatment (mainly PIs and d4T) had lipodystrophy at 3 years. In Gilead 903 13% of d4T/3TC/Efavirenz and 1% of tenofovir/3TC/efavirenz recipients have lipodystrophy, as reported by their physician, at 2 years. Regimens that include a PI (such as Kaletra) have been shown in one prospective study to be associated with faster fat loss than NNRTI (such as efavirenz) based regimens. It is not clear if atazanavir is the same as the 'old' PIs in this regard. Kaletra may be fine to start with but may not be the best choice for a lifetime of treatment

I hope this helps

regards

Graeme Moyle


Previous
will it waste?
Next
supplements for facial wasting?

  
  • Email Email
  • Glossary Glossary


 
 
Advertisement




Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement